Antidiabetic drugs as the future of obesity treatment
DOI:
https://doi.org/10.12775/QS.2024.17.53077Keywords
obesity, diet, physical activity, bariatric surgery, pharmacological methods, semaglutide, tirzepatideAbstract
Obesity is a multifactorial chronic disease with complex pathogenesis. Its causes are considered to be genetic, biological, epigenetic, environmental, developmental and behavioral factors leading to excessive caloric intake and, consequently, weight gain. As body weight increases, the risk of developing many chronic diseases increases and, as a result, life expectancy decreases. The basis of obesity treatment is the introduction of changes in behavior and lifestyle modification, based primarily on the adoption of a healthy, balanced diet with a caloric deficit, regular physical activity and limiting sedentary time. If they are ineffective, pharmacological methods are considered and, if necessary, surgical procedures are performed. Nowadays, more and more attention is paid to obesity as a multifactorial disease that must be effectively treated. It is not only an aesthetic problem but also a serious disease that can lead to premature death. Our work focuses on a review of current methods in the treatment of obesity, with particular attention to the latest pharmacological methods.
References
Papamargaritis D, le Roux CW, Holst JJ, Davies MJ. New therapies for obesity. Cardiovascular Research (2023) 119, 2825–2842
https://doi.org/10.1093/cvr/cvac176
Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules 2022,27,4315
https:// doi.org/10.3390/molecules27134315
Manu P, Lacatusu CM, Rogozea LM, Cernea S. Pharmacological Management of Obesity: A Century of Expert Opinions in Cecil Textbook of Medicine. American Journal of Therapeutics 29, e410–e424 (2022)
Phillips A, Clements JN. Clinical review of subcutaneous semaglutide for obesity.
J Clin Pharm Ther. 2022;47:184–193
DOI: 10.1111/jcpt.13574
Kloock S, Ziegler CG, Dischinger U. Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery? Pharmacology&Therapeutics 251 (2023) 108549
https://doi.org/10.1016/j.pharmthera.2023.108549
Grech VS, Lotsaris K, Grech I, Kefala V, Rallis E. Semaglutide (Ozempic) and obesity. A comprehensive guide for aestheticians. Rev. Clin. Pharmacol. Pharmacokinet. Int. Ed. 38 (Sup1): 31-35 (2024)
https://doi.org/10.61873/RJDB1796
Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23:754–762
DOI: 10.1111/dom.14280
Kosmalski M, Deska K, Bąk B, Różycka-Kosmalska M, Pietras T. Pharmacological Support for the Treatment of Obesity—Present and Future. Healthcare 2023, 11, 433
https://doi.org/10.3390/ healthcare11030433
Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, Srivastava G, Halpern B, Zhang S, Chen J, Bunck MC, Ahmad NN, Forrester T. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature Medicine | Volume 29 | November 2023 | 2909–2918
https://doi.org/10.1038/s41591-023-02597-w
Müllertz ALO, Sandsdal RM, Jensen SBK, Torekov SS. Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety. Obesity Reviews. 2024;25: e13717
wileyonlinelibrary.com/journal/obr
https://doi.org/10.1111/obr.13717
Biertho L, Lebel S, Marceau S, Hould FS, Julien F, Biron S. Biliopancreatic diversion with duodenal switch: surgical technique and perioperative care; Surg Clin North Am (2016)
Mechanick JI, Youdim A, Jones DB, Garvey WT, Hurley DL, McMahon M, Heinberg LJ, Kushner R, Adams TD, Shikora S, Dixon JB, Brethauer S. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery Endocr Pract (2013)
Harris LA, Kayser BD, Cefalo C, Mittendorfer B, Mingrone G, Klein S. Biliopancreatic Diversion Induces Greater Metabolic Improvement Than Roux-en-Y Gastric Bypass; Cell Metabolism 30, 855–864 November 5, 2019 Elsevier Inc.
Kassir R, Debs T, Blanc P, Gugenheim J, Amor IB, Boutet C, Tiffet O. Complications of bariatric surgery: Presentation and emergency management; Int J Surg. 2016 Mar:27:77-81
Hall KD, Guo J. Obesity energetics: body weight regulation and the effects of diet composition. Gastroenterology 2017;152:1718e1727 e1713.
Maclean PS, Bergouignan A, Cornier MA, Jackman MR. Biology’s response to dieting: the impetus for weight regain. Am J Physiol Regul Integr Comp Physiol 2011;301:R581e600.
Contival N, Menahem B, Gautier T, Le Roux Y, Alves A. Guiding the non-bariatric surgeon through complications of bariatric surgery; J Visc Surg. Volume 155, Issue 1, February 2018, Pages 27-40
Pareek M, Schauer PR, Kaplan LM, Leiter LA, Rubino F, Bhatt DL.Metabolic surgery: weight loss, diabetes, and beyond; J Am Coll Cardiol. 2018 Feb 13;71(6):670-687
Abell TL, Minocha A. Gastrointestinal complications of bariatric surgery: diagnosis and therapy; Am J Med Sci. 2006 Apr. 331(4):214-8
Healy P, Clarke Ch, Reynolds I, Arumugasamy M, McNamara D. Complications of bariatric surgery—what the general surgeon needs to know; Surgeon (2016). Volume 14, Issue 2, April 2016, Pages 91-98
Jastreboff AM, Kushner RF. New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics. Annu. Rev. Med. 2023. 74:125–39
https://doi.org/10.1146/annurev-med-043021- 014919
Rohani P, Alamdari NM, Bagheri SE, Hekmatdoost A, Sohouli MH (2023). The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta‐ regression analysis of randomized controlled trials. Front. Endocrinol. 14:1230206
doi: 10.3389/fendo.2023.1230206
Quddos F, Hubshman Z, Tegge A, Sane D, Marti E, Kablinger AS, Gatchalian MK, Kelly AL, DiFeliceantonio AG, Bickel WK. Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity. Scientifc Reports (2023) 13:20998.
https://doi.org/10.1038/s41598-023-48267-2
Feier CVI, Vonica RC, Faur AM, Streinu DR, Muntean C. Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review. Int. J.Mol.Sci.2024,25,4346.
https:// doi.org/10.3390/ijms25084346
Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and
GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus:
from discovery to clinical proof of concept. Mol Metab. 2018;18:3-14.
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP.
Gastroenterology. 2007;132:2131-2157.
Syed, Y.Y. Tirzepatide: First Approval. Drugs 2022, 82, 1213–1220.
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al.
Tirzepatide once weekly for the treatment of obesity. N Engl J Med. (2022) 387:205–16.
doi: 10.1056/NEJMoa2206038
Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al.
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes
(Surmount-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3
trial. Lancet. (2023) 402:613–26. doi: 10.1016/S0140-6736(23)01200-X
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A. Tirzepatide Once Weekly for the Treatment of Obesity; N Engl J Med 2022;387:205-216
Wharton S, Calanna S, Davies M, Dicker D, Goldman B, Lingvay I, Mosenzon O, Rubino DM, Thomsen M, Wadden TA, Pedersen SD. Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss; Diabetes Obes Metab. 2022 Jan; 24(1): 94–105.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Agnieszka Kuzio, Aleksandra Cieplińska, Kinga Ziojła-Lisowska
![Creative Commons License](http://i.creativecommons.org/l/by-nc-sa/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 132
Number of citations: 0